US 11,839,694 B2
Compositions and methods for promoting hemostasis and other physiological activities
Rutledge Ellis-Behnke, Canton, MA (US); Yu-Xiang Liang, Hong Kong (CN); Gerald E. Schneider, Somerville, MA (US); Kwok-Fai So, Hong Kong (CN); David K. C. Tay, Hong Kong (CN); and Shuguang Zhang, Lexington, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); and Versitech Limited, Hong Kong (HK)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and Versitech Limited, Hong Kong (CN)
Filed on Apr. 5, 2016, as Appl. No. 15/091,435.
Application 12/199,670 is a division of application No. 11/411,745, filed on Apr. 25, 2006, granted, now 9,327,010.
Application 15/091,435 is a continuation of application No. 12/199,670, filed on Aug. 27, 2008, granted, now 9,364,513.
Claims priority of provisional application 60/758,827, filed on Jan. 13, 2006.
Claims priority of provisional application 60/674,612, filed on Apr. 25, 2005.
Prior Publication US 2016/0296660 A1, Oct. 13, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61L 26/00 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01)
CPC A61L 26/0047 (2013.01) [A61K 9/0019 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61L 26/0066 (2013.01); A61L 2400/04 (2013.01)] 36 Claims
 
1. A formulation in a dosage form, the formulation forming an ionically crosslinked barrier structure for preventing the movement of bodily fluids and contaminants, comprising self-assembling peptides, wherein the self-assembling peptides consist of from 8 to 32 amino acid residues and consist of one or more amino acid residues selected from the group consisting of Formulas I-IV:
((Xaaneu-Xaa+)x(Xaaneu-Xaa−)y)n  (I)
((Xaaneu-Xaa−)x(Xaaneu-Xaa+)y)n  (II)
((Xaa+-Xaaneu)x(Xaa−Xaaneu)y)n  (III)
((Xaa−-Xaaneu)x(Xaa+Xaaneu)y)n  (IV)
wherein Xaaneu is alanine, valine, glycine, isoleucine, phenylalanine, tyrosine or leucine;
Xaa+ is arginine, lysine or ornithine; Xaa− is aspartic acid or glutamic acid; x and y are integers having a value of 1 or 2, or 4, independently; and n is an integer having a value of 1-4;
wherein the self-assembling peptides are present in an aqueous solution in the dosage form in a concentration between 1.0% weight to volume and 4.0% weight to volume, inclusive, forming an ionically crosslinked self-assembled barrier structure upon contacting physiological fluids or tissues, which prevents passage of a bodily fluid or contaminant through the structure.